Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702077 · ClinicalTrials.gov registry record · NA
Neurofeedback for Tourette Syndrome
A NA study of Tourette Syndrome and Chronic Tic Disorder, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01702077: Completed NA study of Tourette Syndrome and Chronic Tic Disorder, sponsored by Yale University.
NCT01702077 is a NA study of Tourette Syndrome and Chronic Tic Disorder that has completed, run by Yale University. The registered enrollment target is 21 participants, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01702077, a NA study of Tourette Syndrome and Chronic Tic Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to train patients with tic disorders to control activity in a region of their brain that has been associated with the urge to tic. Patients will be given direct feedback regarding activity in this brain area while they are undergoing functional magnetic resonance imaging (fMRI) scanning, and will try to learn to control activity in the region during these feedback sessions. In separate sessions, patients will be given sham feedback based on the brain patterns of a prior subject rather than their own brain patterns. Our primary hypothesis is that the biofeedback training will reduce their tic symptoms more than the sham feedback.
Primary Outcome
A modified version of the Yale Global Tic Severity Scale (YGTSS) will be used, that queries subjects regarding symptoms over the last 3 days (rather than the 2 week period used in the standard scale). Total YGTSS score on this modified scale will be used as the measure of tic severity.
Conditions Studied
Interventions
- PROCEDURE Neurofeedback
- PROCEDURE Sham feedback
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-10 |
| Est. Completion | 2017-12 |
| Phase | NA |
What the finished NCT01702077 record still lists
NCT01702077 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Tourette Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Neurofeedback is the first listed.
NCT01702077 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT01702077 about?
NCT01702077 is a clinical study titled "Neurofeedback for Tourette Syndrome". The aim of this study is to train patients with tic disorders to control activity in a region of their brain that has been associated with the urge to tic. Patients will be given direct feedback regarding activity in this brain area while they are undergoing functional magnetic resonance imaging (fM...
What is the current status of trial NCT01702077?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2012-10. Estimated completion is 2017-12.
What conditions does trial NCT01702077 study?
This clinical trial studies the following conditions: Tourette Syndrome, Chronic Tic Disorder.
What interventions are being tested in trial NCT01702077?
The interventions under investigation include: Neurofeedback (PROCEDURE), Sham feedback (PROCEDURE).
Who is sponsoring clinical trial NCT01702077?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01702077 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01702077's enrollment target sits among peer trials
21 25th of 33 higher than 8 of 33 other Tourette Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tourette Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Remote Delivery of a Mindfulness-based Intervention for Tics
RECRUITING · NA
-
Trajectories of Change in Tourette Syndrome
RECRUITING · NA
-
Clinical Characteristics and Temporal Properties of Individual Tics in Persistent Tic Disorder
RECRUITING · NA
-
Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study
RECRUITING · NA
-
Tourette Deep Brain Stimulation (DBS) Target Detection & Suppression
ACTIVE NOT RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia